Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

20.07 +2.34 (+13.20%)
Streaming Delayed Price Updated: 11:56 AM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,561,056
Open 18.40
Bid (Size) 20.05 (6)
Ask (Size) 20.12 (5)
Prev. Close 17.73
Today's Range 17.32 - 20.40
52wk Range 2.100 - 36.91
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 No-Brainer Healthcare Stocks to Buy in June
Via The Motley Fool
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Via The Motley Fool
Exposures Product Safety

Performance

YTD
+9.4%
+9.4%
1 Month
-16.8%
-16.8%
3 Month
+6.5%
+6.5%
6 Month
+4.6%
+4.6%
1 Year
+739.7%
+739.7%

More News

Read More
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio?
Via Benzinga
Which stocks are experiencing notable movement on Friday?
Via Chartmill
Earnings Scheduled For May 1, 2025
Via Benzinga
Dow Edges Higher; Dell Shares Fall After Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why Summit Therapeutics Plunged Today
Via The Motley Fool
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Top movers in Friday's session
Via Chartmill
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation
Via Stocktwits
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Product Safety
Traders are paying attention to the gapping stocks in Friday's session.
Via Chartmill
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
Via Investor's Business Daily
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint
Via Benzinga
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
From Summit Therapeutics Inc.
Via Business Wire
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Exposures Product Safety
Treasury Yields Top 5%: These 20 Stocks Tanked In Just One Hour
Via Benzinga
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Exposures Economy Legal Product Safety
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
Via Benzinga
Can Summit Therapeutics Stock Double Your Money?
Via The Motley Fool
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Via Benzinga
This Soaring Stock Just Delivered More Good News. Time to Buy?
Via The Motley Fool
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
From Summit Therapeutics Inc.
Via Business Wire
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 20.07
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 06/03/25 11:56 AM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.95B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.